Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review

  • ID: 4281669
  • SWOT Analysis
  • 67 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • GW Pharmaceuticals Plc
  • Vernalis Plc
  • MORE
Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Indivior Plc (Indivior) develops and commercializes medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence in the US. Its pipeline portfolio encompasses buprenorphine-based products, including C4X-3256 in pre-clinical phase for opioid dependence treatment; ADX-71441 in pre-clinical phase for cocaine use disorder; Arbaclofen Placarbil in Phase 1 for alcohol use disorder; and RBP-7000 for schizophrenia. Indivior offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada and the UK. Indivior is headquartered in Slough, the UK.

Indivior Plc Key Recent Developments

Jul 11,2018: Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations
Jun 28,2018: Indivior's Temporary Restraining Order is Extended
May 02,2018: Indivior: Q1 2018 Results
Mar 29,2018: Indivior Enters Into An Exclusive Global License Agreement For C4X Discovery’s Orexin-1 (OX1) Antagonist Program
Feb 15,2018: Indivior Reports Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • GW Pharmaceuticals Plc
  • Vernalis Plc
  • MORE
Section 1 - About the Company
Indivior Plc - Key Facts
Indivior Plc - Key Employees
Indivior Plc - Key Employee Biographies
Indivior Plc - Major Products and Services
Indivior Plc - History
Indivior Plc - Company Statement
Indivior Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Indivior Plc - Business Description
R&D Overview
Indivior Plc - SWOT Analysis
SWOT Analysis - Overview
Indivior Plc - Strengths
Indivior Plc - Weaknesses
Indivior Plc - Opportunities
Indivior Plc - Threats
Indivior Plc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Indivior Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments
Jul 11, 2018: Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations
Jun 28, 2018: Indivior's Temporary Restraining Order is Extended
May 02, 2018: Indivior: Q1 2018 Results
Nov 02, 2017: Indivior: Nine Month Financial Results - FY 2017
Nov 02, 2017: Indivior- Board Committee Changes
Aug 22, 2017: Indivior Opens $30 Million Research and Development Center to Advance Treatment Innovation
Jul 27, 2017: Indivior H1 2017 Financial Results
Feb 22, 2017: Indivior: FY 2016 Financial Results
Feb 03, 2017: Indivior: Director Declaration
Jan 24, 2017: Indivior: Appointment of Non-Executive Director
Section 6 – Appendix
Methodology
Ratio Definitions
About the Publisher
Contact
Disclaimer

List of Tables
Indivior Plc, Key Facts
Indivior Plc, Key Employees
Indivior Plc, Key Employee Biographies
Indivior Plc, Major Products and Services
Indivior Plc, History
Indivior Plc, Subsidiaries
Indivior Plc, Key Competitors
Indivior Plc, Ratios based on current share price
Indivior Plc, Annual Ratios
Indivior Plc, Annual Ratios (Cont...1)
Indivior Plc, Annual Ratios (Cont...2)
Indivior Plc, Interim Ratios
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Indivior Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Indivior Plc, Performance Chart (2013 - 2017)
Indivior Plc, Ratio Charts
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Indivior Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • GW Pharmaceuticals Plc
  • Martindale Pharmaceuticals Ltd
  • Vernalis Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll